<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416621</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00089760</org_study_id>
    <nct_id>NCT03416621</nct_id>
  </id_info>
  <brief_title>Project Q Pilot: Smoking Cessation for Light Smokers</brief_title>
  <official_title>Project Q Pilot: Examining Different Treatment Modalities to Maximize Cessation Efforts for Light Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to evaluate the feasibility, acceptability, and&#xD;
      preliminary efficacy of an intervention to promote smoking cessation among light smokers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The three-arm randomized controlled trial compares Arm 1) standard smoking cessation plus&#xD;
      support text messages, 2) enhanced cue exposure treatment (lab-based + interactive SMS&#xD;
      texting) + D-cycloserine placebo, Arm 3)will include a combination of cognitive behavioral&#xD;
      cessation counseling, enhanced cue exposure treatment (lab-based + interactive SMS texting)&#xD;
      and a cognitive-enhancing drug - D-cycloserine. In addition to an in-person screening visit,&#xD;
      we will conduct three in-person treatment visits and an inperson follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2018</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Completion of at Least 2 Study Visits</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Feasibility will be determined by number of participants that complete at least 2 study visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Rated the Intervention Acceptable</measure>
    <time_frame>Approximately 8 weeks</time_frame>
    <description>Acceptability will be determined by the number of patients rating the intervention usefulness in the experimental and control arms on a 7-point Likert scale, where 1=extremely useless and 7=extremely useful.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Validated Cessation</measure>
    <time_frame>1 week post-intervention</time_frame>
    <description>Biochemically-validated cessation (absence of salivary cotinine) 1 week post-intervention.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Tobacco Use Cessation</condition>
  <arm_group>
    <arm_group_label>Experimental: Cognitive behavioral cessation counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard smoking cessation plus support text messages</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Counseling and placebo drug intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Counseling and active drug intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive behavioral cessation counseling</intervention_name>
    <description>Standard smoking cessation plus support text messages</description>
    <arm_group_label>Active Comparator: Counseling and active drug intervention</arm_group_label>
    <arm_group_label>Experimental: Cognitive behavioral cessation counseling</arm_group_label>
    <arm_group_label>Placebo Comparator: Counseling and placebo drug intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counseling and placebo drug intervention</intervention_name>
    <description>Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo</description>
    <arm_group_label>Placebo Comparator: Counseling and placebo drug intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Counseling and active drug intervention</intervention_name>
    <description>Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
    <arm_group_label>Active Comparator: Counseling and active drug intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥18 years old&#xD;
&#xD;
          -  Able to read and understand English or Spanish&#xD;
&#xD;
          -  Cognitively able to provide informed consent&#xD;
&#xD;
          -  Smoke 1-10 cigs/day on at least 4 days in the past month&#xD;
&#xD;
          -  Express a desire to quit smoking in the next 30 days&#xD;
&#xD;
          -  Access to a cell phone that can send and receive SMS text messages and take and send&#xD;
             pictures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension with a screening blood pressure over 160/100;&#xD;
&#xD;
          -  Hypotension with a screening blood pressure of systolic &lt;90 mm Hg, diastolic &lt;60 mm&#xD;
             Hg;&#xD;
&#xD;
          -  Participants with a history of hypertension may be allowed to participate in the study&#xD;
             if the study physician or physician assistant determines that the condition is stable,&#xD;
             controlled by medication, and in no way jeopardizes the individual's safety;&#xD;
&#xD;
          -  Coronary heart disease, diagnosed by coronary angiogram;&#xD;
&#xD;
          -  History of major heart attack;&#xD;
&#xD;
          -  Major cardiac rhythm disorder determined by study MD;&#xD;
&#xD;
          -  Chest pain in the last month (unless history, exam, indicate a non-cardiac source);&#xD;
&#xD;
          -  Symptomatic cardiac disorder (valvular heart disease, heart murmur, heart failure);&#xD;
&#xD;
          -  Diagnosis of severe liver disease or kidney disorder;&#xD;
&#xD;
          -  Major gastrointestinal problems or disease (Celiac, Crohn's, Ulcerative Colitis)&#xD;
&#xD;
          -  Bleeding ulcers in the past 30 days;&#xD;
&#xD;
          -  Current, advanced lung disorder/disease (COPD, emphysema);&#xD;
&#xD;
          -  Migraine headaches that occur more frequently than once per week;&#xD;
&#xD;
          -  Recent, unexplained fainting spells;&#xD;
&#xD;
          -  Problems giving blood samples;&#xD;
&#xD;
          -  Diabetes not controlled by diet and exercise alone;&#xD;
&#xD;
          -  Current cancer or cancer treatment in the past six months (except basal or squamous&#xD;
             cell skin cancer);&#xD;
&#xD;
          -  HIV, Hepatitis B, or Hepatitis C;&#xD;
&#xD;
          -  History of Tuberculosis or recent positive PPD;&#xD;
&#xD;
          -  Other major medical condition;&#xD;
&#xD;
          -  Current symptomatic, uncontrolled psychiatric disease;&#xD;
&#xD;
          -  Diagnosis of serious mental illness, including bipolar disorder and schizophrenia;&#xD;
&#xD;
          -  Suicidal ideation within the past month or lifetime occurrence of attempted suicide;&#xD;
&#xD;
          -  Current (within 2 weeks) depression determined by PHQ-9 score &gt; 9 or &gt; 0 on item #9&#xD;
&#xD;
          -  Bulimia or anorexia;&#xD;
&#xD;
          -  Pregnant or nursing;&#xD;
&#xD;
          -  Use (within the past 30 days) of:&#xD;
&#xD;
          -  Illegal drugs (or if the urine drug screen is positive for Cocaine, Amphetamine,&#xD;
             Opiates, Methamphetamines, PCP, Benzodiazepines, or Barbiturates), unless prescribed&#xD;
             for management of acute symptoms (tooth extraction, recent surgery);&#xD;
&#xD;
          -  Experimental (investigational) drugs;&#xD;
&#xD;
          -  Psychiatric medications including antidepressants (MAOIs, St. John's Wort), lithium,&#xD;
             anti-psychotics, or any other medications that are known to affect smoking cessation&#xD;
             (e.g. clonidine);&#xD;
&#xD;
          -  Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine patch, nicotine&#xD;
             replacement therapy or any other smoking cessation aid.&#xD;
&#xD;
          -  Use of cigars, cigarillos, pipes, Hookah, dissolvable nicotine, snuff, chewing tobacco&#xD;
             , or e-cigarettes within the past 30 days;&#xD;
&#xD;
          -  Positive result on AUDIT-C;&#xD;
&#xD;
          -  Self-report of marijuana use ≥ 4 days per week;&#xD;
&#xD;
          -  Significant adverse reaction to D-cycloserine in the past;&#xD;
&#xD;
          -  Current or recent (in the past 30 days) participation in another smoking study at our&#xD;
             Center or another research facility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Pollak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center - Cancer Prevention, Detection and Control</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <results_first_submitted>January 5, 2021</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2021</results_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Light Smoker</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03416621/ICF_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03416621/Prot_SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Cognitive Behavioral Cessation Counseling</title>
          <description>Standard smoking cessation plus support text messages&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator: Counseling and Placebo Drug Intervention</title>
          <description>enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages&#xD;
Counseling and placebo drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo</description>
        </group>
        <group group_id="P3">
          <title>Active Comparator: Counseling and Active Drug Intervention</title>
          <description>enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages&#xD;
Counseling and active drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In the comparator standard counseling, one enrolled patient withdrew prior to completing the baseline survey. Three participants in the active comparator arm did not complete the baseline survey.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Cue-based Treatment</title>
          <description>Enhanced cue exposure treatment (lab-based + interactive SMS texting)&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
        </group>
        <group group_id="B2">
          <title>Comparator: Standard Counseling</title>
          <description>Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
        </group>
        <group group_id="B3">
          <title>Active Comparator: Counseling and Active Drug Intervention</title>
          <description>enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages&#xD;
Counseling and active drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" spread="14.8"/>
                    <measurement group_id="B2" value="44.2" spread="18.4"/>
                    <measurement group_id="B3" value="43" spread="24"/>
                    <measurement group_id="B4" value="43.2" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education: Some college or college grad</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment status: Employed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Daily</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Intermittent</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="2.5"/>
                    <measurement group_id="B2" value="6.5" spread="2.0"/>
                    <measurement group_id="B3" value="7" spread="3.6"/>
                    <measurement group_id="B4" value="6.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nicotine Dependence</title>
          <description>Measured by the Fagerstrom Test For Nicotine Dependence (FTND). The FTND has a range of 0-10. The higher the Fagerstrom score, the more intense is the patient's physical dependence on nicotine.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="2.1"/>
                    <measurement group_id="B2" value="2.3" spread="1.7"/>
                    <measurement group_id="B3" value="1.7" spread="2.9"/>
                    <measurement group_id="B4" value="2.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Native Light Smoker</title>
          <description>Native light smoker is defined as a participant smoker who has never smoked more than 10 cigarettes per day</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Completion of at Least 2 Study Visits</title>
        <description>Feasibility will be determined by number of participants that complete at least 2 study visits.</description>
        <time_frame>Approximately 8 weeks</time_frame>
        <population>Only one participant in the &quot;Active Comparator&quot; arm completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Cue-based Treatment</title>
            <description>enhanced cue exposure treatment (lab-based + interactive SMS texting)&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
          </group>
          <group group_id="O2">
            <title>Control: Standard Counseling</title>
            <description>Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
          </group>
          <group group_id="O3">
            <title>Active Comparator: Counseling and Active Drug Intervention</title>
            <description>enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages&#xD;
Counseling and active drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Completion of at Least 2 Study Visits</title>
          <description>Feasibility will be determined by number of participants that complete at least 2 study visits.</description>
          <population>Only one participant in the &quot;Active Comparator&quot; arm completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Rated the Intervention Acceptable</title>
        <description>Acceptability will be determined by the number of patients rating the intervention usefulness in the experimental and control arms on a 7-point Likert scale, where 1=extremely useless and 7=extremely useful.</description>
        <time_frame>Approximately 8 weeks</time_frame>
        <population>The primary outcome was defined as acceptability across the entire sample.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>Standard smoking cessation plus support text messages</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Rated the Intervention Acceptable</title>
          <description>Acceptability will be determined by the number of patients rating the intervention usefulness in the experimental and control arms on a 7-point Likert scale, where 1=extremely useless and 7=extremely useful.</description>
          <population>The primary outcome was defined as acceptability across the entire sample.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Validated Cessation</title>
        <description>Biochemically-validated cessation (absence of salivary cotinine) 1 week post-intervention.</description>
        <time_frame>1 week post-intervention</time_frame>
        <population>Only one participant in the &quot;Active Comparator&quot; arm completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Cue-based Treatment</title>
            <description>enhanced cue exposure treatment (lab-based + interactive SMS texting)&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
          </group>
          <group group_id="O2">
            <title>Control: Standard Counseling</title>
            <description>Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
          </group>
          <group group_id="O3">
            <title>Active Comparator: Counseling and Active Drug Intervention</title>
            <description>Enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages Counseling and active drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Validated Cessation</title>
          <description>Biochemically-validated cessation (absence of salivary cotinine) 1 week post-intervention.</description>
          <population>Only one participant in the &quot;Active Comparator&quot; arm completed the study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Experimental: Cognitive Behavioral Cessation Counseling</title>
          <description>Standard smoking cessation plus support text messages Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator: Counseling and Placebo Drug Intervention</title>
          <description>Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages Counseling and placebo drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo</description>
        </group>
        <group group_id="E3">
          <title>Active Comparator: Counseling and Active Drug Intervention</title>
          <description>Enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.&#xD;
Cognitive behavioral cessation counseling: Standard smoking cessation plus support text messages Counseling and active drug intervention: Enhanced cue exposure treatment (lab-based + interactive SMS texting)+ active DCS. In addition to an in-person, screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Findings are not conclusive due to the pilot nature of the study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kathryn I Pollak</name_or_title>
      <organization>Duke Cancer Institute</organization>
      <phone>919-681-4757</phone>
      <email>kathryn.pollak@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

